Postoperative Adjuvant Chemotherapy for Node-Positive Cervical Adenocarcinoma

2009 ◽  
Vol 19 (2) ◽  
pp. 277-280 ◽  
Author(s):  
Nobuhiro Takeshima ◽  
Kuniko Utsugi ◽  
Katsuhiko Hasumi ◽  
Ken Takizawa
Keyword(s):  
Adjuvant Chemotherapy ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Pelvic Lymphadenectomy ◽  
Cervical Adenocarcinoma ◽  
Postoperative Chemotherapy ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
Node Positive

We examined the effectiveness of postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma. During the period from 1994 to 2002, 98 consecutive patients with clinical stage I and II cervical adenocarcinoma were treated surgically without having undergone any prior treatment. Surgical procedures included radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy. Postoperatively, 21patients were found to have lymph node metastasis, and all were treated with chemotherapy in the absence of radiotherapy. All patients were followed up for at least 5 years. Recurrence developed in 9 of the 21 patients, all 9died of the disease. Six of the 9 recurrences were extrapelvic lesions. Five-year disease-free survival and overall survival were 57% and 67%, respectively. Recurrence was more common in patients with 6 or more positive nodes than in those with fewer than 3 positive nodes. These data suggest the potential role of postoperative chemotherapy for treatments of cervical adenocarcinoma. However, the effectiveness of chemotherapy alone in node-positive cervical adenocarcinoma was likely not as high as that in squamous cell carcinoma. Despite our use of postoperative chemotherapy in the absence of pelvic radiation, the disease recurred predominantly at distant sites.

scholarly journals Prognostic factors and the role of pelvic lymphadenectomy in uterine leiomyosarcomas

2019 ◽  
Vol 7 ◽  
pp. 205031211985681
Author(s):  
Tounsi Nesrine ◽  
Zemni Ines ◽  
Nawel Abdelwahed ◽  
Ayadi Mohamed Ali ◽  
Boujelbene Nadia ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Clinical Stage ◽  
Menopausal Status ◽  
Disease Free Survival ◽  
Pelvic Lymphadenectomy ◽  
Free Survival ◽  
Disease Free ◽  
Lymphovascular Space Invasion

Objectives: Leiomyosarcomas are relatively rare uterine smooth muscle tumors. Surgery is the most common therapy choice for uterine leiomyosarcomas. However, controversy exists over the appropriate initial surgical management, especially about the role of lymph node sampling. The aim of our study is to analyze the prognostic factors and the role of lymphadenectomy in overall survival and in disease-free survival. Methods: We analyzed retrospectively 31 patients suffering from uterine leiomyosarcomas at Institute of Salah Azaiez during 2000–2014. Demographic and clinical features such as age, menopausal status, stage, tumor size, and management options were examined, and pathological characteristics such as mitotic count, lymphovascular space invasion, and tumor necrosis were evaluated. Results: Out of 31 patients treated for uterine leiomyosarcomas, pelvic lymphadenectomy was done for 18 patients. No para-aortic lymphadenectomy was performed. Median number of resected lymph nodes was 13 ± 7 (range: 3–27). Lymphatic metastasis was observed in 2 out of 18 patients with clinical stage IA and IIIB. The distribution of different variables (age, International Federation of Gynecology and Obstetrics stage, tumor size, mitotic count, and adjuvant treatment) between the group of patients, who had or had not lymphadenectomy done, had no significant difference. The 5-year overall survival and disease-free survival were 61% and 50%, respectively. Clinical stage, presence of lymphovascular space invasion, and lymph nodal dissection were found to be relevant for disease-free survival on univariate analysis. Only age and menopausal status were found to be a prognostic factor for overall survival. Conclusion: Hence, routine lymph node dissection was not generally recommended. Our study demonstrates that lymphadenectomy has a statistically significant effect on disease-free survival but not on overall survival.

Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204

2003 ◽  
Vol 21 (24) ◽  
pp. 4592-4596 ◽  
Author(s):  
Nobutoshi Ando ◽  
Toshifumi Iizuka ◽  
Hiroko Ide ◽  
Kaoru Ishida ◽  
Masayuki Shinoda ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Survival Rate ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Disease Free Survival ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
Disease Free

Purpose: We performed a multicenter randomized controlled trial to determine whether postoperative adjuvant chemotherapy improves outcome in patients with esophageal squamous cell carcinoma undergoing radical surgery. Patients and Methods: Patients undergoing transthoracic esophagectomy with lymphadenectomy between July 1992 and January 1997 at 17 institutions were randomly assigned to receive surgery alone or surgery plus chemotherapy including two courses of cisplatin (80 mg/m2 of body-surface area × 1 day) and fluorouracil (800 mg/m2 × 5 days) within 2 months after surgery. Adaptive stratification factors were institution and lymph node status (pN0 versus pN1). The primary end point was disease-free survival. Results: Of the 242 patients, 122 were assigned to surgery alone, and 120 to surgery plus chemotherapy. In the surgery plus chemotherapy group, 91 patients (75%) received both full courses of chemotherapy; grade 3 or 4 hematologic or nonhematologic toxicities were limited. The 5-year disease-free survival rate was 45% with surgery alone, and 55% with surgery plus chemotherapy (one-sided log-rank, P = .037). The 5-year overall survival rate was 52% and 61%, respectively (P = .13). Risk reduction by postoperative chemotherapy was remarkable in the subgroup with lymph node metastasis. Conclusion: Postoperative adjuvant chemotherapy with cisplatin and fluorouracil is better able to prevent relapse in patients with esophageal cancer than surgery alone.

Expression of tripartite motif-containing 44 and its prognostic and clinicopathological values in human malignancies: a meta-analysis

2020 ◽  
Author(s):  
Guoliang Xiao ◽  
Qiuxi Yang ◽  
Ziwei Bao ◽  
Haixia Mao ◽  
Yi Zhang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Advanced Clinical Stage ◽  
Free Survival ◽  
Over Expression ◽  
Tumor Tissues ◽  
Tripartite Motif ◽  
Predictive Role

Abstract Background: Previous researches reported that tripartite motif-containing 44 (TRIM44) were related to prognosis in multiple human tumors. This study was designed to systematically assess the prognostic value of TRIM44 in human malignancies and to describe its possible mechanisms of oncogenesis.Methods: available databases worldwide were searched for eligible studies that evaluated the clinicopathological and prognostic roles of TRIM44 in patients with malignancies.The hazard ratio (HR) and combined odds ratios (ORs) were combined to assess the predictive role of TRIM44 using Stata/SE 14.1 software.Results: A total of 1,740 patients from thirteen original studies were included in this study finally. The results of the combined analysis showed that over-expression of TRIM44 was significantly correlated with shorter overall survival (OS) in cancer patients (HR = 2.16, 95% CI: 1.65–2.83) as well as worse disease-free survival (DFS) (HR= 2.13 (95% CI 1.45 3.11). Additionally, the combined ORs indicated that elevated TRIM44 expression was significantly associated with lymph node metastasis (OR=2.69, 95% CI: 1.71–4.24), distant metastasis (OR=10.35, 95% CI: 1.01-106.24), poor tumor differentiation (OR=1.78, 95% CI: 1.03–3.09), high depth of tumor invasion (OR=2.72, 95% CI: 1.73–4.30), advanced clinical stage (OR=2.75, 95% CI: 2.04-3.71), and recurrence (OR=2.30, 95% CI: 1.34–3.95). Analysis of expression using GEPIA indicated that the expression of TRIM44 was higher in most tumor tissues than the corresponding normal tissues.Survival analysis indicated high levels of TRIM44 mRNA were associated with unfavorable OS and DFS in various malignancies .Conclusions: TRIM44 may serve as a valuable prognostic biomarker and a potential therapeutic target for patients with malignancies.

Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery

2020 ◽  
Vol 30 (5) ◽  
pp. 664-669 ◽  
Author(s):  
Dan Wang ◽  
Shan Zhu ◽  
Congwei Jia ◽  
Dongyan Cao ◽  
Ming Wu ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Disease Free Survival ◽  
Immature Teratoma ◽  
Stage I ◽  
Free Survival ◽  
Fertility Sparing Surgery ◽  
Fertility Sparing ◽  
Staging Surgery ◽  
Disease Free

ObjectiveThe standard treatment for young patients with stage I malignant ovarian germ cell tumors, except stage I dysgerminoma and stage IA G1 immature teratoma, is unilateral salpingo-oophorectomy with complete staging surgery followed by platinum-based chemotherapy. However, the role of complete staging surgery and adjuvant chemotherapy remains controversial. The aim of this study was to investigate the role of complete staging surgery and adjuvant chemotherapy in patients with early-stage pure immature teratoma after fertility-sparing surgery.MethodsPatients with stage I pure immature teratoma who underwent fertility-sparing surgery between January 1986 and June 2018 were reviewed retrospectively. Fertility-sparing surgery was defined as preservation of the uterus and at least one adnexa. The inclusion criteria were age >18 years, stage I disease (confined to one ovary), and diagnosis of pure immature teratoma. Patients with distant metastasis or mixed ovarian germ cell tumor were excluded. Complete staging surgery was defined as peritoneal cytology examination, peritoneal biopsy, omentectomy, or omental biopsy with or without lymph node dissection. Patients designated with stage I disease without complete staging surgery were categorized as stage X. Disease-free survival was defined as the interval from the date of surgery to the date of recurrence or censoring. Disease-free survival curves were calculated using the Kaplan–Meier method and compared using the log-rank test.ResultsA total of 75 patients were included in the analysis, with a median age of 26 years (range 18–40): 26 (34.7%) patients had received complete staging surgery; 51 (68%) patients received postoperative adjuvant chemotherapy while 24 (32%) underwent surgery alone; and 4 patients (5.3%) had recurrent disease during a median follow-up time of 80.2 months (range 13.7–261). The recurrence rates in the chemotherapy group and surveillance groups were 3.9% and 8.3%, respectively (p=0.46). All patients were successfully salvaged, except for one death. Tumor relapse occurred in patients with all grades of immature teratoma (G1: 1/35; G2: 2/25; G3: 1/15). Univariate analysis revealed that complete staging surgery, adjuvant chemotherapy, and tumor grade were not associated with 5 year disease-free survival (p=0.69, p=0.46, p=0.7, respectively). The 5 year disease-free survival rate was 94.6% and the overall survival rate was 98.7%.ConclusionAdult patients with stage I pure immature teratoma had 98.7% overall survival and recurrence rates were low after fertility-sparing surgery.

Taxane-based adjuvant chemotherapy in node positive, early stage Turkish breast cancer patients

Open Medicine ◽  
2009 ◽  
Vol 4 (4) ◽  
pp. 454-458
Author(s):  
Ahmet Alacacioglu ◽  
Baha Zengel ◽  
Ali Denecli
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Node Positive ◽  
Significant Difference ◽  
Disease Free

AbstractAdjuvant chemotherapy decreases the risk of breast cancer recurrence in patients with breast cancer. In addition, it increases the rate of survival. Therefore, various chemotherapy regimens are administered in the treatment of breast cancer. The efficacy of taxane-based adjuvant chemotherapies has been demonstrated in various trials. This trial was designed to retrospectively evaluate the efficacy of taxane-based chemotherapies in lymph node-positive, early-stage Turkish breast cancer patients. 29 patients receiving TAC regimen and 29 patients receiving AC+P regimen were evaluated. 6 courses of TAC regimen were administered every 3 weeks (docetaxel 75 mg/m2, doxorubicine 50 mg/m2, cyclophosphamide 500 mg/m2). The other patient group was administered AC+P regimen (4 courses of doxorubicin 60mg/m2, cyclophosphamide 600 mg/m2 combination every 2 weeks, followed by paclitaxel 175 mg/m2 for 4 courses every 2 weeks). The 1-year, 2-year and 3-year disease-free survival (DFS) rates were 96.3%, 81.1% and 72.8% respectively. No significant difference was detected in DFS between premenopausal and postmenopausal patients on the taxane regimen (p=0.82). There was no significant difference in DFS between estrogen or progesterone receptor positive and negative patients (p=0.46). Disease-free survival of patients receiving TAC and AC+P adjuvant chemotherapy regimen was compared. The follow-up period of patients on AC+P chemotherapy was longer than those receiving TAC (AC+P mean 38.6±12.8 months, TAC mean 17.1±5.4 months). No significant difference was observed upon evaluation of both treatment arms with respect to DFS (p=0.92). In conclusion, this trial once more demonstrated that taxane-based adjuvant chemotherapy was effective and safe in lymph node-positive, early-stage Turkish breast cancer patients.

scholarly journals To Explore the Effect of NLR and PLR on Prognosis of Rectal Cancer on the basis of T3 substage, and to draw the related nomogram

2021 ◽  
Author(s):  
Donglin Li ◽  
Shuang Wang ◽  
Yongping Yang ◽  
Zeyun Zhao ◽  
An Shang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Area Under The Curve ◽  
Disease Free Survival ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
N Stage ◽  
Independent Risk Factors ◽  
Disease Free

Abstract Background: Approximately 50% of patients with rectal cancer are classified into T3 stage, and they are positioned as substage by various criteria. These patients with different neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) develop disparate outcomes. We sought to develop and validate nomograms to predict survival in patients with rectal cancer on the basis of T3 substage.Methods: We conducted a retrospective cohort study by collecting 170 cases from China. Individuals with rectal cancer after 2 or more years of follow up after surgery were eligible for inclusion. Candidate predictors consisted of NLR, PLR, T3 substage and clinical characteristics available at the time of rectal cancer diagnosis. The optimal cut-off values for NLR and PLR were determined using X-Tile (Version 3.6.1) software and were determined before statistical analyses. Variables with P values below 0.1 in the univariable analyses were further evaluated using Cox multivariate analysis. Model discrimination was assessed using receiver operating characteristic (ROC) curve and concordance index (C-index) analysis. Results were internally validated using related software.Results: We analyzed data from 170 patients with T3 rectal cancer. The optimal cut-off value of NLR in relation to overall and disease-free survival were 3.1 and 2.9, and that of PLR were 181.9 and 202.7. Among them, postoperative adjuvant chemotherapy, T3 substage, N stage, CA199 and NLR were independent risk factors affecting overall survival（OS）and disease-free survival (DFS). There was no significant difference in survival rate between T3a and T3b, or between T3c and T3d. The final nomograms of 2-year OS (area under the curve,0.886; The c-index,0.870) and 2-year DFS (area under the curve,0.895; The c-index,0.867) were developed according to independent risk factors analyzed by SPSS 26 (SPSS Inc., Chicago, IL, USA) software. The calibration curves showed negligible optimism.Conclusion: We developed nomograms based on postoperative adjuvant chemotherapy, T3 substage, N stage, CA199 and NLR to help identify patients with poor prognosis and to guide individualized therapy.

High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients

Oncology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Nobuhiro Nakazawa ◽  
Makoto Sohda ◽  
Munenori Ide ◽  
Yuki Shimoda ◽  
Yasunari Ubukata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Amino Acid ◽  
Adjuvant Chemotherapy ◽  
Disease Free Survival ◽  
Amino Acid Transporter ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
Chemotherapy Group ◽  
Acid Transporter ◽  
Disease Free

<b><i>Introduction:</i></b> We investigated whether the expression of L-type amino acid transporter 1 (LAT-1) in clinical gastric cancer (GC) patients could predict patient therapeutic response to postoperative adjuvant chemotherapy. <b><i>Methods:</i></b> Immunohistochemistry was used to investigate LAT-1, CD98, and phosphorylated-mammalian target of rapamycin (p-mTOR) expression in 111 GC patients. To clarify whether LAT-1 influences the therapeutic effects of chemotherapy, the correlation between disease-free survival rates and LAT-1 was determined in 2 groups: 59 patients who did not undergo postoperative adjuvant chemotherapy and 52 patients who did undergo postoperative adjuvant chemotherapy. <b><i>Results:</i></b> LAT-1 was significantly correlated with CD98 and p-mTOR expressions. We did not find any statistically significant correlation between LAT-1 and recurrence in the nontreated group. In contrast, a significant association was found between LAT-1 expression and disease-free survival in the chemotherapy group. Moreover, multivariate regression analysis demonstrated that LAT-1 was an independent predictor of disease-free survival in the postoperative adjuvant chemotherapy group (<i>p</i> = 0.012). <b><i>Conclusion:</i></b> Our findings demonstrate that LAT-1 is a useful predictive marker for a successful postoperative adjuvant chemotherapy treatment.

Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.

1998 ◽  
Vol 16 (4) ◽  
pp. 1601-1612 ◽  
Author(s):  
M A Dimopoulos ◽  
L A Moulopoulos
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Carcinoma ◽  
Disease Free Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Muscle Invasive ◽  
Disease Free

PURPOSE The standard treatment for patients with muscle-invasive carcinoma of the urinary bladder is radical cystectomy. While radical cystectomy cures many patients with this tumor, almost 50% of them will develop metastatic disease. Adjuvant chemotherapy has been proposed for these patients in an attempt to reduce the probability of relapse and to improve survival. To assess whether adjuvant chemotherapy does benefit patients with muscle-invasive bladder cancer, we reviewed all phase II and III studies published in the English literature over the last 20 years. METHODS A review of all published reports was facilitated by the use of Medline computer search and by manual search of the Index Medicus. RESULTS Several comparative, nonrandomized studies have indicated that adjuvant chemotherapy may prolong disease-free survival. Four randomized studies have been conducted and all had a suboptimal patient accrual. Three studies used a cisplatin-containing combination chemotherapy and included primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder. All three studies indicated that adjuvant chemotherapy improved disease-free survival and two of them also showed improvement in event-free survival and overall survival, respectively. CONCLUSION Published series have been unable to establish an undisputed benefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder cancer. The interpretation of the available data is compromised by several methodologic and statistical problems. Thus, adjuvant chemotherapy cannot be considered as a standard treatment for all patients with muscle-invasive carcinoma of the bladder. Well-designed prospective randomized studies are needed to clarify the role of adjuvant chemotherapy in this disease. However, outside a protocol setting, there is some evidence that patients with extravesical disease or with lymph node involvement may benefit from adjuvant treatment with cisplatin-based combination chemotherapy. No data support such an approach for patients with muscle-invasive but organ-confined bladder cancer.

Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7537-7537 ◽  
Author(s):  
Xue-Ning Yang ◽  
Gang Cheng ◽  
Xiao-song Ben ◽  
Hong-He Luo ◽  
Chang-li Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Stage ◽  
Indirect Comparison ◽  
Disease Free Survival ◽  
Free Survival ◽  
Stage Ib ◽  
Iiia Nsclc ◽  
Disease Free

7537 Background: Adjuvant chemotherapy is the standard of care for completely resected stage 2-3 non-small cell lung cancer(NSCLC). A few trials suggest neoadjuvant chemotherapy is a promising mode for resectable NSCLC. Indirect comparison meta-analysis of adjuvant versus neoadjuvant therapy showed no difference in survival. This study was conducted to determine whether neoadjuvant chemotherapy or adjuvant chemotherapy prolongs disease-free survival among patients with resectable NSCLC. Methods: Patients with clinical stage IB-IIIA NSCLC were eligible. Patients were randomly assigned to 3 cycles of neoadjuvant DC (Docetaxel: 75mg/m2, Carboplatin :AUC=5 on day 1 every 3wk),followed by surgery 3-6 wk after chemotherapy, or surgery followed by 3 cycles of adjuvant DC at the same schedule. The primary end point was 3 years Disease Free Survival(DFS); secondary end points were 3 years Overall Survival rate (OS) and Safety. Planned sample size is 410. Results: Between March 2006 and May 2011, 198 patients have been accrued, 97 in the neoadjuvant arm, 101 in the adjuvant arm. The neoadjuvant arm had more patients received chemotherapy( 100% v.s 85.1%, P<0.001 ) and received 3 cycles( 91.8% v.s82.6%, P=0.061) than adjuvant arm. Both arms are well tolerated to DC chemotherapy. The most common grade 3/4 adverse event is neutropenia (41.2% with neoadjuvant arm v.s 31.7% with adjuvant arm). One chemotherapy related death in adjuvant arm. One patient die of perioperative pulmonary embolism in neoadjuvant arm. No difference in peri-operative complication between two arms. The 3 years DFS was 45% in the neoadjuvant arm and 53% in the adjuvant arm, HR=0.88 (0.58-1.33), P=0.54. Median survival has not been reached in both arms. Conclusions: Neoadjuvant or adjuvant chemotherapy with docetaxel plus carboplatin in resectable clinical stage IB-IIIA NSCLC is feasible and safe. Preliminary results show similar 3 years DFS in both arms. The OS data has not matured in both arms. Clinical trial information: NCT00321334.

Role of adjuvant chemotherapy in patients with locally advanced rectal carcinoma after preoperative chemoradiotherapy: Single center experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15147-e15147
Author(s):  
Mikhail Fedyanin ◽  
Alexey Tryakin ◽  
Kheda Elsnukaeva ◽  
Sergey Gordeev ◽  
Olga Sekhina ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Rectal Carcinoma ◽  
Clinical Stage ◽  
Locally Advanced ◽  
Prospective Trial ◽  
Disease Free Survival ◽  
Preoperative Chemoradiotherapy ◽  
Single Center Experience ◽  
National Guidance

e15147 Background: Various national guidance provide different approaches in adjuvant chemotherapy for locally advanced rectal carcinoma initially treated with preoperative chemoradiotherapy. We evaluated the efficacy of adjuvant chemotherapy depending on the clinical stage of disease (prior to chemoradiotherapy) and yp stage (after surgery). Methods: Preoperative chemoradiotherapy was administered in 457 patients with locally advanced rectal carcinoma. Radiotherapy was performed in pts receiving capecitabine (64%), intravenous administration of 5-FU (16%) or combination fluoropyrimidines with oxaliplatin (20%). Adjuvant chemotherapy was administered in 98 patients (21%) (fluoropyrimidines alone (20%) or in combination with oxaliplatin (80% patients). Overall survival (OS) was the primary endpoint. Statistical analysis was performed in IBM SPSS statistics v.20 software package. Results: the mean age of patients was 56.6 years, male - 56%. Median of follow up was 42 months (2-141). Adjuvant chemotherapy did not result to better OS in any of clinical stage (p = 0.6 HR 1.1, 95% CI 0.6-2.1). However adjuvant chemotherapy tended to improve disease free survival (DFS) in stage ypT0-4N1-2M0 (р=0.1, HR=0.6, 95%CI 0.4-1.1). Subanalysis showed significant improvement of DFS in patients with ypT1-4N2M0: median of DFS in patients with adjuvant chemotherapy was 62 months, in patients from group of surveillance – 16 months (р<0.01, HR=0.3, 95%CI 0.14-0.7) and a tendency to improvement of OS (table). Conclusions: Our retrospective data confirmed the results of ADORE prospective trial, and showed that adjuvant chemotherapy for locally advanced rectal carcinoma after chemoradiotherapy should be administered only in patients with residual positive lymph nodes (yp stage III). [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document